Carcinoid of the Extra-Hepatic Bile Duct: A Case Report with Long-Term Follow-up and Review of Literature

2008 ◽  
Vol 74 (1) ◽  
pp. 87-90 ◽  
Author(s):  
Niraj J. Gusani ◽  
J. Wallis Marsh ◽  
Michael A. Nalesnik ◽  
Mitchell E. Tublin ◽  
T. Clark Gamblin
Keyword(s):  
Bile Duct ◽  
Carcinoid Tumor ◽  
Extrahepatic Bile Duct ◽  
Strong Support ◽  
Complete Excision ◽  
Term Survival ◽  
Long Term Survival ◽  
Long Term Follow Up

Extrahepatic bile duct tumors, 80 per cent of which are adenocarcinomas, are rare neoplasms accounting for less than two per cent of all cancers. Carcinoid tumor of the extrahepatic bile ducts is a reportable lesion, with only approximately 50 cases described in the literature since 1959. We present a case of a primary extrahepatic bile duct carcinoid tumor resected for cure with the longest reported follow-up time (11 years) after surgery. We also summarize the existing literature with regard to this rare tumor. Our case lends strong support to the notion that extrahepatic biliary carcinoids are generally indolent lesions that, if aggressively resected, can result in excellent long-term survival. Complete excision with clear margins seems to provide the best chance of obtaining long-term survival and cure.

scholarly journals LTBK-12. EORTC 26951, RANDOMIZED STUDY OF ADJUVANT PCV AFTER 59.4 GY RADIOTHERAPY: VERY LONG TERM FOLLOW-UP

2019 ◽  
Vol 21 (Supplement_6) ◽  
pp. vi285-vi285
Author(s):  
Martin van den Bent ◽  
Khe Hoang-Xuan ◽  
Alba Brandes ◽  
Johan Kros ◽  
M C M Kouwenhoven ◽  
...  
Keyword(s):  
Randomized Study ◽  
Progression Free Survival ◽  
Phase Iii ◽  
Term Survival ◽  
Long Term Survival ◽  
Kaplan Meier ◽  
Tumor Group ◽  
Long Term Follow Up

Abstract BACKGROUND Between 1995 and 2002 the EORTC Brain Tumor Group conducted a prospective phase III study on adjuvant procarbazine, CCNU and vincristine (PCV) chemotherapy in anaplastic oligodendroglioma (AOD). A mature follow-up presented in 2012 showed survival benefit of the addition of PCV, in particular in 1p/19q co-deleted tumors and tumors with MGMT promoter methylation. We now present very long term follow-up. MATERIALS AND METHODS Patients were eligible if locally diagnosed with a newly diagnosed AOD. They were randomized between radiotherapy (RT, 33 x 1.8 Gy) and the same RT followed by 6 cycles PCV (RT/PCV). Primary endpoints were overall survival (OS) and progression free survival (PFS). 1p/19q status (FISH) was determined in 300 patient. Kaplan- Meier technique and Cox modeling were used for long term survival analysis. Primary analyses were adjusted for known prognostic factors. For other analyses no adjustment was performed. RESULTS With 368 patients included, a median follow-up of 18.4 years and 307 (83%) survival events, median and 20-year survival after RT/PCV versus RT alone were 42.3 mo and 16.8% vs 30.6 months and 10.1% (HR 0.78; 95% CI (0.63, 0.98), adjusted p=0.06). Eighty patients were 1p/19q codel of which 26 (33%) were still alive, in this subgroup median and 20-year survival after RT/PCV versus RT alone were 14 years and 37.1% versus 9.3 years and 13.6% (HR 0.60, 95% CI (0.35, 1.03), unadjusted p=0.06). Twenty year PFS in 1p/19q codel was 31.3% in RT/PCV treated patients and 10.8% in RT only treated patients (HR 0.49, 95% CI (0.29, 0.83), unadjusted p=0.007). In the 1p/19q codel subgroup age, WHO PS and necrosis at pathology were identified to be of independent prognostic value for OS. CONCLUSION This long term analysis confirms the earlier conclusions and provides data on long term survival in this patient group. In 1p/19q codel patients treated with RT/PCV, the 20-year PFS and OS rates are 31% and 37% respectively.

scholarly journals Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial

2021 ◽  
Vol 11 ◽  
Author(s):  
Lili Mao ◽  
Ya Ding ◽  
Xue Bai ◽  
Xinan Sheng ◽  
Jie Dai ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cutaneous Melanoma ◽  
Objective Response ◽  
Chinese Patients ◽  
Term Survival ◽  
Long Term Survival ◽  
Acral Melanoma ◽  
Long Term Follow Up

ObjectivesTo examine the long-term survival outcome of dabrafenib in combination with trametinib in Chinese patients with unresectable or metastatic acral/cutaneous melanoma with BRAF-V600 mutation and to explore potential predictors of effectiveness.MethodsThis was a long-term follow-up of Chinese patients with unresectable or metastatic BRAF V600-mutant acral/cutaneous melanoma administered dabrafenib (150 mg twice daily) plus trametinib (2 mg once daily) in an open-label, multicenter, single-arm, phase IIa study (NCT02083354). Efficacy endpoints included objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). The impacts of baseline characteristics on PFS and OS were analyzed.ResultsA total of sixty patients were included. The median age was 48 years, and 24 patients (40.0%) were male. Totally 12 individuals (20.0%) had acral melanoma, and 45 (75.0%) had failed previous systemic therapy. Up to July 2020, the median duration of follow-up was 37.0 (95% confidence interval [CI] 29.1-44.9) months. The updated ORR was 71.7% (95%CI 60.3%-83.1%). The 3-year OS rate was 28.8% (95%CI 19.1-43.6%) in the overall population, and 35.7% (95%CI 15.5–82.4%) in acral melanoma patients. The median DOR was 7.5 months (95%CI 4.5 to 10.5). Baseline normal lactic dehydrogenase (LDH), metastatic organ sites<3 and complete response to combination therapy with dabrafenib plus trametinib were associated with improved PFS and OS.ConclusionDabrafenib combined with trametinib confer long-term survival in Chinese patients with BRAF V600-mutant, unresectable or metastatic acral/cutaneous melanoma.Clinical Trial Registrationhttps://clinicaltrials.gov/ct2/show/NCT02083354, identifier NCT02083354.

scholarly journals A Long-term Survival Case of Hepatic Metastasis from Cancer of the Extrahepatic Bile Duct Treated with Hepatectomy

2009 ◽  
Vol 42 (9) ◽  
pp. 1501-1505
Author(s):  
Hiroyuki Shinchi ◽  
Yukou Mataki ◽  
Hiroshi Kurahara ◽  
Shinichi Maeda ◽  
Fumitake Kubo ◽  
...  
Keyword(s):  
Bile Duct ◽  
Hepatic Metastasis ◽  
Extrahepatic Bile Duct ◽  
Term Survival ◽  
Long Term Survival ◽  
Survival Case

scholarly journals Long-Term Survival After Composite Mechanical Aortic Root Replacement

Aorta ◽  
2016 ◽  
Vol 04 (04) ◽  
pp. 146-147
Author(s):  
Khaled Al-Ebrahim ◽  
Husain Jabbad ◽  
Ahmad Alqari
Keyword(s):  
Aortic Root ◽  
Mechanical Valve ◽  
Composite Graft ◽  
Aortic Root Replacement ◽  
Term Survival ◽  
Long Term Survival ◽  
Long Term Follow Up

AbstractThis report describes the long-term follow-up of the repair of a giant ascending aneurysm using a composite graft with a mechanical valve.

Intraperitoneal Chemotherapy for Ovarian Carcinoma: Results of Long-Term Follow-Up

2002 ◽  
Vol 20 (3) ◽  
pp. 694-698 ◽  
Author(s):  
Richard R. Barakat ◽  
Paul Sabbatini ◽  
Dharmendra Bhaskaran ◽  
Margarita Revzin ◽  
Alex Smith ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Prognostic Factors ◽  
Residual Disease ◽  
Term Survival ◽  
Long Term Survival ◽  
Cox Proportional Hazard ◽  
Kaplan Meier ◽  
Long Term Follow Up

PURPOSE: To determine long-term survival and predictors of recurrence in a retrospective cohort of patients with epithelial ovarian cancer treated with intraperitoneal (IP) chemotherapy. PATIENTS AND METHODS: Records were reviewed of 433 patients who received IP therapy for ovarian cancer between 1984 and 1998; follow-up data were available for 411 patients. IP therapy was provided as consolidation therapy (n = 89), or for treatment of persistent (n = 310) or recurrent (n = 12) disease after surgery and initial systemic therapy; therapy usually consisted of platinum-based combination therapy. Statistical analysis included tests for associations between potential prognostic factors, and between prognostic factors and survival. Survival probabilities were estimated by Kaplan-Meier methods, and prognostic factors for survival were evaluated by a Cox proportional hazard model. RESULTS: The mean age of patients was 52 years (range, 25 to 76 years). Distribution by stage and grade was as follows: stage I, 7; II, 24; III, 342; IV, 52; not available (NA), 8; and grade 1, 30; 2, 99; and 3, 289; NA, 15. The median survival from initiation of IP therapy by residual disease was none, 8.7 years; microscopic, 4.8 years; less than 1 cm, 3.3 years; more than 1 cm, 1.2 years. In a multivariate analysis, the only significant predictors of long-term survival were grade and size of residual disease at initiation of IP therapy. CONCLUSION: Prolonged survival was observed in selected patients receiving IP platinum-based therapy. It is not possible to determine the contribution of IP therapy to survival in this study. A relationship between size of disease at the initiation of IP therapy and long-term survival was demonstrated.

scholarly journals A radiostereometric and clinical long-term follow-up study of the surface replacement trapeziometacarpal joint prosthesis

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Bart ten Brinke ◽  
Nina M. C. Mathijssen ◽  
Ian F. Blom ◽  
Lennard A. Koster ◽  
Gerald A. Kraan
Keyword(s):  
Clinical Outcomes ◽  
Joint Prosthesis ◽  
Surface Replacement ◽  
Trapeziometacarpal Joint ◽  
Term Survival ◽  
Long Term Survival ◽  
Follow Up Study ◽  
Long Term Follow Up

Abstract Background The aim of this study was to determine long-term survival and clinical outcomes of the surface replacement trapeziometacarpal joint prosthesis (SR™TMC) and to evaluate implant migration using radiostereometric analysis (RSA). Methods In this clinical long-term follow-up study outcomes of ten patients who received the SR™TMC joint prosthesis were evaluated using DASH and Nelson scores, Visual Analogue Scale (VAS) of pain, and key pinch strength. RSA-radiographs were obtained direct postoperatively and 6 months, 1, 5 and 10 years postoperatively and were analyzed using model-based RSA software. Results During follow-up, two early revisions took place. Mean pre-operative DASH and Nelson scores were 54 (SD 15) and 54 (SD 17), improved significantly after 6 months (DASH 25 (SD 20), Nelson 75 (SD 18)) and remained excellent during long-term follow-up in all patients with a stable implant. At final follow-up, clinical scores deteriorated clearly in two patients with a loose implant in situ. Conclusions Long-term survival of the SR™TMC joint prosthesis is relatively poor. However, clinical outcomes improved significantly in the short-term and remained excellent in the long-term in those patients with a stable implant, but deteriorated clearly in case of loosening. The role of RSA in TMC joint arthroplasty is potentially valuable but needs to be further investigated. Several challenges of RSA in the TMC joint have been addressed by the authors and suggestions to optimize RSA-data are given. Trial registration This study was registered in the Netherlands Trial Register (NL7126).

scholarly journals Prognostic Factors for Long-Term Survival after Surgical Resection of Primary Cardiac Sarcoma

2019 ◽  
Vol 67 (08) ◽  
pp. 665-671 ◽  
Author(s):  
Anas Aboud ◽  
Kassar Farha ◽  
Wan Chin Hsieh ◽  
Frank Brasch ◽  
Stephan Ensminger ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Ki 67 ◽  
Term Survival ◽  
Long Term Survival ◽  
Long Term Follow Up ◽  
Synovial Sarcomas ◽  
Histological Characteristics ◽  
Primary Cardiac Sarcoma

Background Primary cardiac sarcoma (CS) is an extremely rare disease. This study aims to identify possible prognostic factors for long-term survival. Methods A total of 17 consecutive patients who were treated for primary CS between 2003 und 2018 at two cardiac centers were investigated. Clinical data and histological characteristics of the tumors were analyzed. Long-term follow-up of all patients were performed. Results The median age was 54 years (range: 23–74). The tumors originated from the left side of the heart in nine patients. Histologically, there were four angiosarcomas, three intimal sarcomas, and three synovial sarcomas. One- and 7-year survivals were 81.9 and 18.2%, respectively. Low expression levels of Ki-67 tended to be associated with increased survival (log-rank p = 0.06). Adjuvant chemotherapy but not radiotherapy regardless of existing metastases was associated with significantly increased survival (log-rank p = 0.001). Conclusion Angiosarcoma was the most common type of CS. The survival of CS patients is poor but prognostic factors, such as Ki-67, may help estimate the course of the disease. Survival could be improved significantly with chemotherapy.

The Importance of the Thickness of the Femoral Cement Mantle

2003 ◽  
Vol 13 (2) ◽  
pp. 61-64 ◽  
Author(s):  
W.H. Harris
Keyword(s):  
Femoral Stem ◽  
Cement Mantle ◽  
Grading System ◽  
Term Survival ◽  
Long Term Survival ◽  
Increased Risk ◽  
Long Term Follow Up ◽  
Mantle Thickness

The importance of mantle thickness in the long-term survival of cemented femoral components remains controversial. One complexity in evaluating mantle thickness alone is the dominating fact that so many other factors can influence the incidence of failure. Nonetheless, a cement grading system has been applied to the assessment of the intermediate and long-term follow-up series of the following cemented femoral stem designs HD-2 (Howmedica, Rutherford, NJ), CAD (Howmedica, Rutherford, NJ), Precoat (Zimmer, Warsaw, IN), Iowa (Zimmer, Warsaw, IN), Ti32 (Zimmer, Warsaw, IN), and DF80 (Zimmer, Warsaw, IN). In each series, a statistically significant increased risk of failure was found in those cases with cement mantles that were thin or deficient. While these data do not mean that all such cases fail, the data strongly support the concept of avoiding such deficiencies in the cement mantle of these stem designs.

Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 554-554 ◽  
Author(s):  
Michael J. Overman ◽  
Francesca Bergamo ◽  
Raymond S. McDermott ◽  
Massimo Aglietta ◽  
Franklin Chen ◽  
...  
Keyword(s):  
Term Survival ◽  
Long Term Survival ◽  
Dna Mismatch ◽  
Long Term Follow Up ◽  
Group A ◽  
Grade 3 ◽  
Group B ◽  
Line Setting

554 Background: Nivolumab (NIVO) provided durable responses (ORR, 32% per central assessment) and disease control (DCR, 64%) in pre-treated pts with dMMR/MSI-H mCRC (NCT02060188; Overman MJ et al Lancet Oncol 2017). NIVO was approved in the US for pts with dMMR/MSI-H mCRC who progress after standard chemotherapy (SC) with a fluoropyrimidine (F), oxaliplatin (Ox), and irinotecan (Iri). Here we present long-term survival and outcomes by prior chemotherapy with NIVO in CheckMate-142. Methods: Pts with dMMR/MSI-H mCRC received NIVO 3 mg/kg Q2W. The primary endpoint was ORR per RECIST 1.1. Other endpoints were DCR, DOR, PFS, OS, and safety/tolerability. Results: Of 74 pts evaluated, 53 had received F, Ox and Iri (group A); 21 pts had ≤ 2 SC regimens (group B). Median follow-up was 21 mo. Efficacy by central assessment is shown in the Table. In the 74 pts, ORR was 34%; CRs increased from 3% in prior database lock (DBL) to 9%. Numerically higher responses were noted in group B vs group A (Table). Grade 3–4 TRAEs were reported in 20% (all pts), 25% (group A), and 10% (group B) of pts. No treatment-related deaths were reported. Conclusions: NIVO continued to provide clinically meaningful durable responses and long-term overall survival in pts with dMMR/MSI-H mCRC. Of note, CR rate increased with longer follow-up. No new safety signals were reported with long-term follow-up. Enhanced responses in pts with ≤ 2 SC regimens support ongoing evaluation of NIVO combinations in first-line setting. Clinical trial information: NCT02060188. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document